On 14 November, at the 2026 conference on high-quality development of innovative drugs in Suzhou, the 2026 national drug list for basic medical insurance, maternity insurance and work injury insurance was published together with the commercial health insurance innovative drug list. According to the notice issued that day by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, and to a Xinhua report on 15 November, 107 drugs were added, 51 of them class 1 innovative drugs, a record high. Thirty-four drugs were removed because their clinical value was limited, better alternatives existed, or information fields in their package inserts were incomplete and supply could not be maintained. Taking additions, removals and the merging of dosage forms together, the list gained 78 numbering entries net and now contains 3,331 drugs: 1,935 Western medicines and 1,396 traditional Chinese patent medicines. The commercial insurance list added 12 drugs and now holds 28. The new list takes effect on 1 January 2027.
For patients these figures mean what medicines will cost; for pharmaceutical companies they mean market access. For people working with languages, they turn into a stack of documents whose names have to be aligned again. The phrase about incomplete information fields in the package insert deserves a second reading: it puts the completeness of a written document among the reasons a product may leave the list. Once the list expands, package inserts, patient information leaflets, registration dossiers, and medical records and prescriptions brought back from treatment abroad all need a fresh edition.

What the list records is a legal name, not a brand
Several names can appear on one box of medicine, but the one the list cites and the one a package insert must display is the approved generic name. The naming principles drawn up by the Chinese Pharmacopoeia Commission state that a drug must follow the rule of "one drug, one name", that names should be scientific, unambiguous and short, and that English names should as far as possible adopt the International Nonproprietary Names (INN) compiled by the World Health Organization. A generic name may not be taken from a brand name, and neither the generic name nor its dedicated stems may be registered as a trademark. One active ingredient can carry several brand names across manufacturers, but it has only one legal name.
In translation this becomes very concrete. If a Chinese insert uses the generic name while a foreign-language document keeps only the brand name, the two texts appear to describe different medicines. Conversely, translating a brand name as though it were a generic name into a patient leaflet sends the reviewer on an unnecessary detour. The administration notice also says that this year the names of traditional Chinese medicine decoction pieces were adjusted in line with the 2025 edition of the Chinese Pharmacopoeia, with some varieties merged under one numbering entry, leaving 885 decoction pieces. When a name changes, the old wording in earlier materials should be marked as a former name rather than quietly erased.
An incomplete information field is not a layout detail
The notice describes the removals as covering drugs of limited clinical value, drugs with better alternatives, or drugs whose package insert information fields were incomplete and which could not be supplied. That last clause is documentary in nature. A complete insert has fixed places for the drug name, composition, indications, dosage and administration, adverse reactions, contraindications, precautions, storage, shelf life, approval number and manufacturer. The real risk in multilingual versions is not an inelegant sentence but a field lost in translation, typesetting or version replacement, or a statement that no longer matches another document.
Such gaps are hard to see in a single file. They usually surface only when a whole set is compared side by side: the registration dossier gives one strength, the patient leaflet another; the Chinese version has a section on paediatric use while the foreign version keeps only a vague general warning. A safer method is to list the fields first, tick them off one by one, and only then polish the prose. Producing a first draft with machine translation and having a human check it field by field is more valuable on this kind of document than on ordinary copy, because a missing field will never be corrected by a feel for style.
Between publication and effect, the terminology table costs the most
There is a little over a month between publication in November and implementation on 1 January 2027. Pharmaceutical companies need to update packaging and inserts; hospitals need to revise formularies and patient instructions; patient groups need to rewrite explanatory material; people treated abroad arrive with foreign prescriptions and ask what a medicine is called at home. None of these texts exists in isolation. They share one set of drug names, dosage forms, strengths and indications, and if one is updated while another is not, a difference appears that someone will have to explain.
So the first task is often not translation but a table: the legal Chinese name in the list, the corresponding INN English name, common brand names, former names, and the way dosage forms and strengths are written, set out for everyone on the project. Only after the table is settled is the work divided, a machine draft produced, every field checked by a person, and a cross-check run against the list before delivery. Reverse the order and the usual result is a full batch rework. The small comparison table that kept being revised in our company note about a community service day is the same idea in miniature.
A set of documents has to corroborate itself
The 107 additions cover areas of urgent clinical need such as oncology, rare diseases, chronic conditions and psychiatric disorders, and include advanced therapies entering the list for the first time. The more novel the treatment, the more mixed the material a patient holds: the insert, an informed consent form, a dosing schedule, reimbursement notes, records from treatment overseas. If a name, a dosage unit, a date format or a batch number differs in one place, the reviewer or the doctor has to stop and ask. Individually these details look trivial; together they decide whether a set of documents can corroborate itself.
From where we sit, this is consistency work. Whether it is pharmaceutical insert translation or the post-editing check on medical records and consent forms, the point is that one way of saying things runs through all of them. Why a single medicine carries three names, and which of them may be changed, is unpacked more fully in our translator note that begins with a former Chinese drug name. An expanded list is good news; getting that good news onto paper still depends on writing every field in full and aligning every name.
